Logo image of CTMX

CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

NASDAQ:CTMX - Nasdaq - US23284F1057 - Common Stock - Currency: USD

2.12  +0.21 (+10.99%)

Premarket: 2.15 +0.03 (+1.42%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CTMX. CTMX was compared to 549 industry peers in the Biotechnology industry. CTMX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CTMX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

CTMX had positive earnings in the past year.
In the past year CTMX has reported a negative cash flow from operations.
CTMX had negative earnings in 4 of the past 5 years.
In the past 5 years CTMX reported 4 times negative operating cash flow.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of CTMX (27.41%) is better than 98.18% of its industry peers.
CTMX has a Return On Equity of 40.02%. This is amongst the best in the industry. CTMX outperforms 98.18% of its industry peers.
CTMX has a Return On Invested Capital of 25.08%. This is amongst the best in the industry. CTMX outperforms 98.18% of its industry peers.
Industry RankSector Rank
ROA 27.41%
ROE 40.02%
ROIC 25.08%
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K

1.3 Margins

Looking at the Profit Margin, with a value of 34.01%, CTMX belongs to the top of the industry, outperforming 96.90% of the companies in the same industry.
Looking at the Operating Margin, with a value of 30.56%, CTMX belongs to the top of the industry, outperforming 97.09% of the companies in the same industry.
Industry RankSector Rank
OM 30.56%
PM (TTM) 34.01%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

7

2. Health

2.1 Basic Checks

CTMX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CTMX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CTMX has been increased compared to 5 years ago.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.94, we must say that CTMX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.94, CTMX is in the better half of the industry, outperforming 64.30% of the companies in the same industry.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.94
ROIC/WACC2.59
WACC9.69%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.20 indicates that CTMX has no problem at all paying its short term obligations.
The Current ratio of CTMX (4.20) is comparable to the rest of the industry.
CTMX has a Quick Ratio of 4.20. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.20, CTMX is in line with its industry, outperforming 49.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 4.2
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

4

3. Growth

3.1 Past

CTMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 306.43%, which is quite impressive.
CTMX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.01%.
The Revenue has been growing by 19.15% on average over the past years. This is quite good.
EPS 1Y (TTM)306.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.75%
Revenue 1Y (TTM)18.01%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-25.71%

3.2 Future

CTMX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.72% yearly.
CTMX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.51% yearly.
EPS Next Y-155.58%
EPS Next 2Y-75.21%
EPS Next 3Y-54.3%
EPS Next 5Y-6.72%
Revenue Next Year-27.42%
Revenue Next 2Y-33.28%
Revenue Next 3Y-47.27%
Revenue Next 5Y1.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 3.72, which indicates a rather cheap valuation of CTMX.
Based on the Price/Earnings ratio, CTMX is valued cheaper than 98.72% of the companies in the same industry.
CTMX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.82.
The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 3.72
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CTMX indicates a rather cheap valuation: CTMX is cheaper than 99.45% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.85
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

A cheap valuation may be justified as CTMX's earnings are expected to decrease with -54.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-75.21%
EPS Next 3Y-54.3%

0

5. Dividend

5.1 Amount

No dividends for CTMX!.
Industry RankSector Rank
Dividend Yield N/A

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (8/18/2025, 9:26:05 PM)

Premarket: 2.15 +0.03 (+1.42%)

2.12

+0.21 (+10.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners49.81%
Inst Owner Change194.58%
Ins Owners0.63%
Ins Owner Change1.75%
Market Cap349.61M
Analysts84.62
Price Target5.87 (176.89%)
Short Float %16.19%
Short Ratio8.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.1%
Min EPS beat(2)98.72%
Max EPS beat(2)113.47%
EPS beat(4)4
Avg EPS beat(4)141.82%
Min EPS beat(4)98.72%
Max EPS beat(4)215.22%
EPS beat(8)8
Avg EPS beat(8)146.11%
EPS beat(12)10
Avg EPS beat(12)101.81%
EPS beat(16)11
Avg EPS beat(16)73.27%
Revenue beat(2)2
Avg Revenue beat(2)42.82%
Min Revenue beat(2)23.76%
Max Revenue beat(2)61.87%
Revenue beat(4)4
Avg Revenue beat(4)66.28%
Min Revenue beat(4)23.76%
Max Revenue beat(4)92.34%
Revenue beat(8)8
Avg Revenue beat(8)60.6%
Revenue beat(12)10
Avg Revenue beat(12)36.87%
Revenue beat(16)10
Avg Revenue beat(16)12.56%
PT rev (1m)4.55%
PT rev (3m)53.33%
EPS NQ rev (1m)15.68%
EPS NQ rev (3m)31.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-2528.57%
Revenue NQ rev (1m)-2.13%
Revenue NQ rev (3m)-31.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.05%
Valuation
Industry RankSector Rank
PE 3.72
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B 2.92
P/tB 2.95
EV/EBITDA 1.85
EPS(TTM)0.57
EY26.89%
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.86
BVpS0.73
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 27.41%
ROE 40.02%
ROCE 31.75%
ROIC 25.08%
ROICexc N/A
ROICexgc N/A
OM 30.56%
PM (TTM) 34.01%
GM N/A
FCFM N/A
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 15.57%
Cap/Sales 0.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 4.2
Altman-Z 0.94
F-Score6
WACC9.69%
ROIC/WACC2.59
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)306.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.75%
EPS Next Y-155.58%
EPS Next 2Y-75.21%
EPS Next 3Y-54.3%
EPS Next 5Y-6.72%
Revenue 1Y (TTM)18.01%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-25.71%
Revenue Next Year-27.42%
Revenue Next 2Y-33.28%
Revenue Next 3Y-47.27%
Revenue Next 5Y1.51%
EBIT growth 1Y654.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.83%
OCF growth 3YN/A
OCF growth 5YN/A